Skip to content
lifestyle.usfeatures.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ALX Oncology
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
September 28, 2026
ALX Oncology to Present at Upcoming Investor Conferences in September
September 2, 2026
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
June 30, 2026
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
June 30, 2026
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
June 1, 2026
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 22, 2026
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
May 22, 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
May 20, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
April 17, 2026
1
2
Next Page
→